Gender- Male / Female: no. (%) |
7(35) / 13(65) |
Age: Mean (years) ± SD |
55 ± 17 |
Time since PAH diagnosis - yr |
4 ± 4 |
PAH classification |
|
IPAH |
12 (60) |
CTD-PAH |
6 (30) |
Group 5 PH (Sarcoid) |
1 (5) |
Mixed disease |
1 (5) |
WHO functional class – no. (%) |
|
I |
0 |
II |
10 (50) |
III |
10 (50) |
IV |
0 |
6-Minute walk distance* – Mean (meters) ± SD |
331 ± 165 |
Risk stratification |
|
Low risk |
5 (25) |
Intermediate risk |
13 (65) |
High risk |
2 (10) |
Baseline medications for PAH – no. (%) |
|
ERA+ PD5 inhibitors |
17 (85) |
ERA + sGC stimulator |
1 (5) |
ERA+ PD5 inhibitors + PGI2 therapy |
2 (10) |
Baseline medications (excluding targeted PAH med.) – no. (%) |
|
None |
1 (5) |
1-2 |
10 (50) |
3-6 |
7 (35) |
>7 |
2 (10) |
Co-morbidities |
|
None |
3 (15) |
Respiratory |
11 (55) |
Cardiovascular |
4 (20) |
Gastrointestinal |
4 (20) |